CP
NVO

Covenant Partners’s Novo Nordisk NVO Stock Holding History

Covenant Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,991
Closed -$552K – 143
2025
Q2 		$552K Sell
7,991
-3,094
-28% -$210K 0.16% 66
2025
Q1 		$770K Sell
11,085
-6,311
-36% -$521K 0.25% 48
2024
Q4 		$1.5M Sell
17,396
-130
-0.7% -$14.1K 0.46% 27
2024
Q3 		$2.09M Buy
17,526
+130
+0.7% +$17.3K 0.61% 20
2024
Q2 		$2.48M Hold
17,396
– – 0.75% 17
2024
Q1 		$2.23M Hold
17,396
– – 0.65% 17
2023
Q4 		$1.8M Hold
17,396
– – 0.57% 18
2023
Q3 		$1.58M Sell
17,396
-390
-2% -$34.4K 0.57% 17
2023
Q2 		$1.44M Buy
17,786
+390
+2% +$31.9K 0.52% 20
2023
Q1 		$1.38M Buy
17,396
+3,948
+29% +$280K 0.53% 22
2022
Q4 		$910K Buy
+13,448
New +$788K 0.37% 41

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Covenant Partners's NVO Position: Q3 2025 in Review

Covenant Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 7,991 shares — an estimated $552K sold.

Covenant Partners first reported a position in NVO in Q4 2022 and held it in 11 quarters. The position peaked at $2.48M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • Covenant Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • Covenant Partners sold 7,991 Novo Nordisk shares in Q3 2025, an estimated $552K.
  • Covenant Partners first reported a position in Novo Nordisk in Q4 2022 and held it in 11 quarters.
  • Covenant Partners's Novo Nordisk position peaked at $2.48M in Q2 2024.
  • 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on Covenant Partners's 13F filing for Q3 2025, filed 24 Oct 2025.